PO-09 Spironolactone as Add-On Therapy to Chlorthalidone Improves Endothelial Function, Arterial Stiffness and Insulin Resistance in European and African American Patients with Essential Hypertension — A Double-Blind Placebo-Controlled Randomized Study
Diuretics have been shown to have a neutral effect on cardiovascular (CV) biomarkers like arterial stiffness and endothelial function despite their blood pressure (BP) lowering effect. Thiazide diuretics generally have harmful effects on glucose metabolism, however, the effect of mineralo-corticoid...
Gespeichert in:
Veröffentlicht in: | Artery research 2014, Vol.8 (4), p.169-169 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Diuretics have been shown to have a neutral effect on cardiovascular (CV) biomarkers like arterial stiffness and endothelial function despite their blood pressure (BP) lowering effect. Thiazide diuretics generally have harmful effects on glucose metabolism, however, the effect of mineralo-corticoid receptor antagonists on insulin resistance in essential hypertension (eHTN) is only partially elucidated. We hypothesized that chlorthalidone (CHT) in combination with spironolactone (SPL) results in better arterial compliance then CHT therapy alone through additional improvement of glucose metabolism parameters.
Methods
This double-blind placebo-controlled randomized single center study aimed to identify SPL add-on therapy to CHT treatment alone on CV risk markers such as BP, 24-h ambulatory blood pressure monitoring (24-H ABPM), aortic BP (aBP), augmentation index (AIx), pulse wave velocity (cfPWV), flow-mediated dilation (FMD), fasting glucose, plasma insulin levels and insulin sensitivity (by homeostasis model assessment: HOMA-IR). A total of 34 patients (21.7% male, 40% white) were randomized to either CHT 25 mg + Placebo or CHT 25 mg + SPL 25 mg once daily. At baseline and after 3 months office BP, 24-H ABPM, markers of arterial stiffness, FMD, fasting glucose, plasma insulin levels and HOMA-IR.
Results
The study showed statistically significant improvements after three months in patients treated with CHT+ SPL in clinic BP, 24-hour ABPM, FMD, markers of arterial stiffness, and glucose metabolism. In detail, clinic SBP (131.5±14.6 to 119.1 ±14.3 mmHg (P = 0.034), aortic SBP (122±13 vs 113±13.7 mm Hg, p = 0.048), 24-H ABPM SBP (151.5±15.1 to 131.7 ±10.4 mm Hg, p = 0.0049, 24-H ABPM DBP 83.2±6.1 to 74 ±9.3 mm Hg, p = 0.032, 24-H ABPM. Fasting plasma glucose, plasma insulin levels decreased and insulin sensitivity (by homeostasis model assessment: HOMA-IR) improved with SPL as compared to CHT alone (
p |
---|---|
ISSN: | 1872-9312 1876-4401 1876-4401 |
DOI: | 10.1016/j.artres.2014.09.015 |